|
Please confirm that the title of the tutorial
|
Personal information
Name:
Street Address:
Street Address:
City, State, Zip Code:
VOICE #:
Special
Needs:
E-mail Address:
Work telephone #:
Work FAX # :
TEST: Radionuclide Therapy
|
1. Which one of the following statements is NOT true?: The ideal effective half-life of a therapeutic radiopharmaceutical is 1.5 x procedure length In a beta/gamma emitter like I-131, the ratio of tissue damage is ~ 90% beta/10% gamma Target-to-non target ratio is more critical therapeutically than diagnostically Particulate
emission is preferable to photon emission for therapy |
|
2. Which one of the following radioisotopes has no current applications in therapeutic Nuclear Medicine?:Y-90 I-131 P-32 Sr-85 |
|
3. NRC Group 5 Radiopharmaceuticals include: Generators Diagnostic Radiopharmaceuticals Therapeutic Radiopharmaceuticals not requiring hospitalization Therapeutic
Radiopharmaceuticals requiring hospitalization |
|
4. Of the four types of thyroid cancer,: Follicular and anaplastic are treatable, the others are not Follicular and papillary are treatable, the others are not Papillary and medullary are treatable, the others are not Papillary and anaplastic are
treatable, the others are not |
|
5. For a hyperthyroid patient with a 50% uptake, treatment with 10 mCi of I-131 NaI solution results in a thyroid dose of approximately: 10 Rads 100 Rads 1,000
Rads 10000
Rads |
|
6. For a hyperthyroid patient undergoing treatment with 10 mCi of I-131 NaI solution for hyperthyroidism, the patient is advised that it will take ____ weeks to begin to observe beneficial effects and ____ weeks to reach the maximum beneficial effect.: 2, 6 1, 12 4-6, 12 12-24 |
|
7. The long-term side effect following a successful treatment of hyperthyroidism with I-131 NaI solution is: thyroid carcinoma hypothyroidism
aplastic
anemia |
|
8. According to the current NRC and Agreement State regulations, the release criterion for a patient hospitalized for treatment of a thyroid cancer patient with I-131 NaI solution is a reading of: 5 mR/hr and 5 mR/hr at 1 m from patient’s chest 5 mR/hr and 7 mR/hr at 1 m from patient’s chest 7 mR/hr and 5 mR/hr at 1 m from patient’s chest 7 mR/hr and 7 mR/hr at 1 m
from patient’s chest |
|
9. Which one of the following statements is NOT true?: Use
of Sr-89 chloride for treating pain from bony metastases is palliative and not
curative Use of Sr-89 chloride for treating pain from bony metastases has an overall response rate of ~ 80% Sr-89 chloride for treating pain from bony metastases may cause pain to flare up before a positive response is obtained. Use
of 4 mci of Sr-89 for treating pain from bony metastases confers a bone marrow
radiation dose of ~25 R |
|
10. Which ONE of the following statements regarding successful treatment of polycythemia vera with P-32 is FALSE?: Increases median survival time 8-fold Often
requires two 4-mCi doses for effective treatment The pharmaceutical used is P-32 chromic phosphate colloid Bone marrow dose exceeds 200 R for a 4 mCi dose 11% of successfully treated patients eventually develop leukemia |
|
11. Which of the following therapies involves use of an unsealed source in the body? Brachytherapy Teletherapy
Radiopharmaceutical
Therapy |
|
12. Which of the following therapeutic radioisotopes places the dose administrator at greatest risk? I-131 P-32
Sr-89 |
|
13. Typical prescribed doses for treating Graves Disease and Plummer’s Disease are, respectively, 8 mCi and 25 mCi 25 mCi and 8 mCi
15 mCi and 50 mCi 25 mCi and 25 mCi |
|
14. If the first dose of I-131 NaI administered for treating hyperthyroidism or thyroid carcinoma fails to adequately treat the patient, the second dose should be equal to... 50% of the first dose 100% of the first dose
150% of the first dose
Same as the first dose |
|
15. In
the decay scheme of I-131 printed below, the gamma ray used for imaging is... gamma
3 gamma 9
gamma
13 |
|
16. Since the decay scheme displayed above indicates that there are 14 gamma rays and 6 beta particles emitted by I-131, then the ratio of tissue damage caused by beta particles compared to gamma rays is: 6/14 6/20
14/20 |
|
17. Which ONE of the following statements is TRUE? Women are more likely to develop hyperthyroidism and are more difficult to treat than men Women are more likely to develop hyperthyroidism and are less difficult to treat than men
Women are less likely to
develop hyperthyroidism and are more difficult to treat than men |
|
18. Which one of the following statements describes the FDA approved indication for palliation of bone pain with Sr-89 chloride? Patient presents with bone pain and requests Sr-89 therapy Patient with bone pain caused by bony metastases from breast or prostate cancer but no other primary malignancy
Patient with bone pain caused
by bony metastases from osteosarcoma but no other primary malignancy |
|
19. Which ONE of the following statements is FALSE? The biological distribution of Sr-89 is essentially identical to that of Tc-99m MDP Sr is a Ca analog
Therapy
with Sr-89 is both palliative
and curative |
|
20. Typical injected dose of Sr-89 chloride is: 0.4 mCi 4 mCi
40 mCi |
|
21. Typical injected dose of P-32 Na phosphate for treating Polycythemia Vera is: 0.4 mCi 4 mCi
40 mCi |
|
22. P-32 CrPO4 colloid is suitable for treating malignant effusions in women with ovarian carcinoma. The route of injection is: intravenous intracavitary
intraarterial subcutaneous |
|
23. Which one of the following is NOT required for a high dose therapy for thyroid cancer?: After patient is released, the room must be surveyed by Radiation Safety before being occupied by the next patient Everyone involved in the patient’s care must wear a film badge
Everyone involved in the
patient’s care must provide a urine specimen to check for I-131 excretion |
|
24. Which ONE of the following statements regarding both Sr-89 and I-131 is TRUE? Both decay by b+ emission Both decay by b- emission Both emit g photons along with the b particles
The
radiation risk to the person administering the dose would be Both require hospitalization until patient reading is <5 mR/hr at 1 m from |
|
25. Which
one of the following protocols is used for Bexxar and Zevalin in the
radioimmunotherapy of non-Hodgkins Lymphoma? 5 mCi dosimetric dose on day 1, therapeutic dose on day 3 5 mCi dosimetric dose on day 1, therapeutic dose on day 8
5 mCi dosimetric dose on day 1,
therapeutic dose on day 21 |
 | |
|
